Generating and using real-world data: A worthwhile uphill battle

Cell. 2024 Mar 28;187(7):1636-1650. doi: 10.1016/j.cell.2024.02.012.

Abstract

The precision oncology paradigm challenges the feasibility and data generalizability of traditional clinical trials. Consequently, an unmet need exists for practical approaches to test many subgroups, evaluate real-world drug value, and gather comprehensive, accessible datasets to validate novel biomarkers. Real-world data (RWD) are increasingly recognized to have the potential to fill this gap in research methodology. Established applications of RWD include informing disease epidemiology, pharmacovigilance, and healthcare quality assessment. Currently, concerns regarding RWD quality and comprehensiveness, privacy, and biases hamper their broader application. Nonetheless, RWD may play a pivotal role in supplementing clinical trials, enabling conditional reimbursement and accelerated drug access, and innovating trial conduct. Moreover, purpose-built RWD repositories may support the extension or refinement of drug indications and facilitate the discovery and validation of new biomarkers. This perspective explores the potential of leveraging RWD to advance oncology, highlights its benefits and challenges, and suggests a path forward in this evolving field.

Keywords: oncology; precision oncology; real-world data; real-world evidence.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Humans
  • Medical Oncology
  • Neoplasms*
  • Precision Medicine
  • Research Design

Substances

  • Biomarkers